戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 fective, modify or change therapy, and avoid disease complications.
2 herence is common and results in preventable disease complications.
3  of disease predisposition or development of disease complications.
4 clinical problem that mediates most vascular disease complications.
5 ients susceptible to disease reactivation or disease complications.
6 rly posttransplant to prevent cardiovascular disease complications.
7 atients, 78 (9%) of whom experienced Crohn's disease complications.
8 ar, coronary artery, and peripheral arterial diseases) complications.
9 disease, which represents an underrecognized disease complication and contributes to excess morbidity
10 because of the frequency of this spectrum of disease complication and its potential for severe VA imp
11 y for adult WAS patients with severe chronic disease complications and for whom an allogeneic procedu
12 normalities are more severe in patients with disease complications and in those with a greater degree
13 individuals because they are at high risk of disease complications and mortality.
14  and for calculating individualized risks of disease complications and response to therapy.
15 k for advanced heart failure symptoms, other disease complications, and HCM-related mortality, and la
16 tics with emphasis on specific locations and disease complications, and the differential diagnosis co
17 ains or strains more likely to cause serious disease complications are causally associated with speci
18 of patients with PV or ET is near-normal and disease complications are effectively (and safely) manag
19 natural course of PNH, reducing symptoms and disease complications as well as improving survival to a
20 ntral pathogenic event in the lethal malaria disease complication, cerebral malaria.
21  African Americans with SSc have more severe disease complications compared to Caucasians with SSc, a
22 18 biochemical tests, complete blood counts, disease complications, duration of hospital admission, a
23 mpered our abilities to recognize individual disease complications, especially in the rarer forms.
24 ricular apical aneurysms experienced adverse disease complications (event rate, 10.5%/y), including s
25 es was defined by self-report of diabetes or disease complication, fasting glucose level of 6.9 mmol/
26  restore vascular NO signaling and attenuate disease complications in patients with hemolysis.
27                                        Major disease complications include thrombosis and leukemic or
28 e also been meager in terms of treatment for disease complications, including anemia, splenomegaly, a
29 resence and extent of several characteristic disease complications, including basilar impression, spi
30 has been prominently associated with adverse disease complications, including sudden death or heart f
31 ised patients with influenza had more severe disease/complications, longer viral shedding, and more a
32 he morbidity from SCA, but prevention of all disease complications may require minimizing the fractio
33         Notably, RAP-536 treatment mitigated disease complications of IE, including iron overload, sp
34 strointestinal bleeding, small bowel Crohn's disease, complications of coeliac disease and surveillan
35 psy remains the gold standard for staging of disease, complications of this procedure and other well-
36 hanisms of nerve injury including infectious diseases, complication of medical diseases, and mechanic
37 CD (children who have not yet suffered overt disease complications or only had mild problems) is cont
38 of survival appear to be those related to RA disease complications, specifically, extraarticular mani
39 consider therapeutic approaches to metabolic disease complications such as diabetic nephropathy.
40 ntral role in the development of more severe disease complications, such as mitten deformities of han
41 th cystic fibrosis an understanding of those disease complications that will require surgical consult
42 thors describe the signs and symptoms of the disease, complications that arise, and expected outcome
43                   A competing-risk model for disease complications was derived and validated in indep

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。